En Es
Categorías

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initia ...
Productos Covid-19NoticiasResumen
Close

Covid-19 QIAGEN

Laboratorio clínico

Flu A/SARS-CoV-2 Test
NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test

The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test is a multiplex polymerase chain reaction (PCR) test that detects and differentiates influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes. The respiratory test takes advantage of the NeuMoDx 96 and NeuMoDx 288 molecular systems’ automated three-step workflow and has obtained CE-IVD approval for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit, which includes a collection vial, stabilization tube and pipette.
Mas detalles

SARS-CoV-2 Assay
NeuMoDx SARS-CoV-2 Assay

The NeuMoDx SARS-CoV-2 Assay is a real-time RT-PCR diagnostic test intended for the qualitative detection of SARS-CoV-2 coronavirus RNA in nasal, nasopharyngeal and oropharyngeal swabs in transport medium, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider. This test is performed on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems and is also for use with saliva specimens that are collected within a healthcare setting by individuals using the NeuMoDx Saliva Collection Kit when determined to be appropriate by a healthcare provider.
Mas detalles

Molecular System
NeuMoDx 96

The NeuMoDx 96 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Consisting of the instrument with touchscreen computer, accessories, and reagents and consumables, the system is intended for in vitro diagnostic (IVD) use in performing NeuMoDx-validated nucleic acid testing in clinical laboratories.
Mas detalles

Molecular System
NeuMoDx 288

The NeuMoDx 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Consisting of the instrument with touchscreen computer, accessories, and reagents and consumables, the instrument is intended for in vitro diagnostic (IVD) use in performing NeuMoDx-validated nucleic acid testing in clinical laboratories.
Mas detalles

SARS-CoV-2 Antigen Test
QIAreach SARS-CoV-2 Antigen Test

The QIAreach SARS-CoV-2 Antigen Test is a scalable, digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen that allows testing up to eight patients simultaneously for SARS-CoV-2 infection with the first positive results in just two minutes. As part of the complete QIAreach solution for SARS-CoV-2 testing, the test will run simultaneously with the QIAreach Anti-SARS-CoV-2 Total Test on a single QIAreach eHub.
Mas detalles

SARS-CoV-2 Antibody Test
QIAreach Anti-SARS-CoV-2 Total Test

The QIAreach Anti-SARS-CoV-2 Total Test is a rapid, digital lateral flow serological test, using nanoparticle fluorescence, intended for qualitative detection of total antibodies to SARS-CoV-2 in human serum and plasma (heparin, EDTA). It is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Mas detalles

Respiratory SARS-CoV-2 Panel
QIAstat-Dx Respiratory SARS-CoV-2 Panel

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is a multiplex syndromic cartridge that detects and differentiates 21 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM). It offers an intuitive workflow with less than one-minute hands-on time and provides comprehensive qualitative results in about an hour.
Mas detalles
Close

Noticias of QIAGEN

QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short

14 Aug 2020
QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Más info

QIAGEN Enters into Agreement to Acquire STAT-Dx

13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Más info

Qiagen Acquires Bioinformatics Firm OmicSoft

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Más info
Close

Sobre QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
Facebook Twitter Google+ Linked in
PRUEBA PIK3CA

PRUEBA PIK3CA

Modelo: PIK3CA RGQ PCR Kit
Solicite información

Descripción:

El kit PIK3CA RGQ PCR es la primera prueba diagnóstica complementaria aprobada por la FDA para identificar pacientes con cáncer de mama avanzado. La prueba se basa en la detección de mutaciones específicas de PIK3CA en el ADN tumoral.


Enviar un mensaje al proveedor

* Información requerida
* Email:
Para
QIAGEN (PRUEBA PIK3CA)
* Mensaje

Derecho de autor © 2000-2020 TradeMed.com. Todos los derechos reservados. | Términos y condiciones